nach oben

Erschienen in:

12.02.2016 | Brief Report

A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome

verfasst von: Paolo G. Arduino, Adriana Cafaro, Marco Garrone, Alessio Gambino, Marco Cabras, Ercole Romagnoli, Roberto Broccoletti

Erschienen in: Lasers in Medical Science | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Comparison between low-level laser therapy (LLLT) and clonazepam for treating burning mouth syndrome (BMS) patients has never been documented; the aim of this study was to assess the effects of LLLT photobiomodulation versus medical therapy with clonazepam on BMS. Thirty-three patients (25 female, 8 male, mean age = 67.12) were randomly allocated to two different groups: the first one (group A, 18 patients) underwent two laser irradiation sessions weekly for 5 weeks, whereas the second one (group B, 15 patients) received topical clonazepam therapy [half a tablet (2 mg) in the mouth without swallowing for 3 min, three times a day for 21 days]. LLLT was delivered with a continuous wave 980-nm aluminum gallium arsenide (AlGaAs) diode laser and the output of 300 mW, delivering a Fluence of 10 J/cm², using a “spot technique,” with an average power density of about 1 W/cm². The laser probe was held perpendicularly at a distance of about 2 mm from the mucosa. Visual analogue scale (VAS), McGill Pain Questionnaire, present pain intensity (PPI), and Oral Health Impact Profile (OHIP-49) assessed sensation of pain. Hospital Anxiety and Depression Scale and Geriatric Depression Scale assessed levels of anxiety and depression. Twelve weeks after the end of treatment, patients treated with LLLT experienced a decrease in pain sensation reported for all the parameters analyzed: VAS (P = 0.004), McGill Pain Questionnaire (P = 0.002), PPI (P = 0.002), and OHIP-49 (P = 0.010). The group treated with clonazepam had less favorable results for VAS (P = 0.33), McGill Pain Questionnaire (P = 0.005), PPI (P = 0.013), and OHIP-49 (P = 0.25). Levels of anxiety and depression did not change statistically in any groups (P > 0.05). Comparing the two groups, LLLT appeared to be superior in improving pain perception, but statistically only at 8 weeks after the end of the protocol proposed (P = 0.026). Based on this preliminary trial, LLLT is capable of reducing the symptoms of patients with BMS with a constant and long-lasting effect, experienced since the end of the first applications.

Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders. Cepahalalgia 24(S1): 8–160

Sun A, Wu KM, Wang YP, Lin HP, Chen HM, Chiang CP (2013) Burning mouth syndrome: a review and update. J Oral Pathol Med 42:649–655CrossRefPubMed

Silvestre FJ, Silvestre-Rangil J, López-Jornet P (2015) Burning mouth syndrome: a review and update. Rev Neurol 60:457–463PubMed

Miziara I, Chagury A, Vargas C, Freitas L, Mahmoud A (2015) Therapeutic options in idiopathic burning mouth syndrome: literature review. Int Arch Otorhinolaryngol 19:86–89CrossRefPubMedPubMedCentral

de Moraes M, do Amaral Bezerra BA, da Rocha Neto PC, de Oliveira Soares AC, Pinto LP, de Lisboa Lopes Costa A (2012) Randomized trials for the treatment of burning mouth syndrome: an evidence-based review of the literature. J Oral Pathol Med 41:281–287CrossRefPubMed

Spanemberg JC, López JL, de Figueiredo MA, Cherubini K, Salum FG (2015) Efficacy of low-level laser therapy for the treatment of burning mouth syndrome: a randomized, controlled trial. J Biomed Opt 20:98001CrossRef

Pezelj-Ribarić S, Kqiku L, Brumini G et al (2013) Proinflammatory cytokine levels in saliva in patients with burning mouth syndrome before and after treatment with low-level laser therapy. Lasers Med Sci 28:297–301CrossRefPubMed

dos Santos LF, Carvalho Ade A, Leão JC, Cruz Perez DE, Castro JF (2011) Effect of low-level laser therapy in the treatment of burning mouth syndrome: a case series. Photomed Laser Surg 29:793–796CrossRef

Kato IT, Pellegrini VD, Prates RA, Ribeiro MS, Wetter NU, Sugaya NN (2010) Low-level laser therapy in burning mouth syndrome patients: a pilot study. Photomed Laser Surg 28:835–839CrossRefPubMed

10.

Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558CrossRefPubMedPubMedCentral

11.

Sawasaki I, Geraldo-Martins VR, Ribeiro MS, Marques MM (2009) Effect of low-intensity laser therapy on mast cell degranulation in human oral mucosa. Lasers Med Sci 24:113–116CrossRefPubMed

12.

Parker S (2007) Low-level laser use in dentistry. Br Dent J 202:131–138CrossRefPubMed

13.

Pozza DH, Fregapani PW, Blessmann Weber JB et al (2008) Analgesic action of laser therapy (LLLT) in an animal model. Med Oral Patol Oral Cir Buccal 13:E648–52

14.

Yang HW, Huang YF (2011) Treatment of burning mouth syndrome with a low-level energy diode laser. Photomed Laser Surg 29:123–125CrossRefPubMed

15.

Romeo U, Del Vecchio A, Capocci M, Maggiore C, Ripari M (2010) The low level laser therapy in the management of neurological burning mouth syndrome. Pilot Study Annali Stomatologia 1:14–18

16.

Sancakli E, Gökçen-Röhlıg B, Balık A, Öngül D, Kıpırdı S, Keskın H (2015) Early results of low-level laser application for masticatory muscle pain: a double-blind randomized clinical study. BMC Oral Health 15:131CrossRefPubMedPubMedCentral

17.

Ozturan S, Sirali A, Sur H (2015) Effects of Nd:YAG laser irradiation for minimizing edema and pain after sinus lift surgery: randomized controlled clinical trial. Photomed Laser Surg 33:193–199CrossRefPubMed

18.

Eslamian L, Borzabadi-Farahani A, Hassanzadeh-Azhiri A, Badiee MR, Fekrazad R (2014) The effect of 810-nm low-level laser therapy on pain caused by orthodontic elastomeric separators. Lasers Med Sci 29:559–564CrossRefPubMed

19.

Gasperini G, de Rodrigues Siqueira IC, Rezende Costa L (2014) Does low-level laser therapy decrease swelling and pain resulting from orthognathic surgery? Int J Oral Maxillofac Surg 43:868–873CrossRefPubMed

20.

Venancio Rde A, Campari CM, Lizarelli Rde F (2005) Low intensity laser therapy in the treatment of temporomandibular disorders: a double-blind study. J Oral Rehabil 32:800–807CrossRefPubMed

21.

Gremeau-Richard C, Woda A, Navez ML et al (2004) Topical clonazepam in stomatodynia: a randomised placebo-controlled study. Pain 108:51–57CrossRefPubMed

22.

de Rodríguez Rivera Campillo E, López-López J, Chimenos-Küstner E, de Rodríguez RCE (2010) Response to topical clonazepam in patients with burning mouth syndrome: a clinical study. Bull Group Int Rech Sci Stomatol Odontol 49:19–29

23.

Amos K, Yeoh SC, Farah CS (2011) Combined topical and systemic clonazepam therapy for the management of burning mouth syndrome: a retrospective pilot study. J Orofac Pain 25:125–130PubMed

24.

Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale. Updated Lit Rev J Psychosom Res 52:69–77CrossRef

25.

Almeida OP, Almeida SA (1999) Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. Int J Geriatr Psychiatry 14:858–865CrossRefPubMed

26.

Malik R, Goel S, Misra D, Panjwani S, Misra A (2012) Assessment of anxiety and depression in patients with burning mouth syndrome: a clinical trial. J Midlife Health 3:36–39PubMedPubMedCentral

27.

Schiavone V, Adamo D, Ventrella G et al (2012) Anxiety, depression, and pain in burning mouth syndrome: first chicken or egg? Headache 52:1019–1025CrossRefPubMed

28.

Bogetto F, Maina G, Ferro G, Carbone M, Gandolfo S (1998) Psychiatric comorbidity in patients with burning mouth syndrome. Psychosom Med 60:378–385CrossRefPubMed

29.

Ni Riordain R, Moloney E, O’Sullivan K, McCreary C (2010) Burning mouth syndrome and oral health-related quality of life: is there a change over time? Oral Dis 16:643–674CrossRefPubMed

30.

Aframian DJ, Ofir M, Benoliel R (2010) Comparison of oral mucosal pH values in bulimia nervosa, GERD, BMS patients and healthy population. Oral Dis 16:807–811CrossRefPubMed

Titel: A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome
verfasst von: Paolo G. Arduino
Adriana Cafaro
Marco Garrone
Alessio Gambino
Marco Cabras
Ercole Romagnoli
Roberto Broccoletti
Publikationsdatum: 12.02.2016
Verlag: Springer London
Erschienen in: Lasers in Medical Science / Ausgabe 4/2016
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI: https://doi.org/10.1007/s10103-016-1897-8

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Evaluation of the effects of pulsed wave LLLT on tibial diaphysis in two rat models of experimental osteoporosis, as examined by stereological and real-time PCR gene expression analyses

The impact of Er:YAG laser enamel conditioning on the microleakage of a new hydrophilic sealant—UltraSeal XT® hydro™

Influence of lasing parameters on the cleaning efficacy of laser-activated irrigation with pulsed erbium lasers

Action of antimicrobial photodynamic therapy on heterotypic biofilm: Candida albicans and Bacillus atrophaeus

Efficacy of high-intensity laser therapy in the treatment of chronic neck pain: a randomized double-blind placebo-control trial

Minimally invasive, non-ablative Er:YAG laser treatment of stress urinary incontinence in women—a pilot study